TORONTO, Feb. 9, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announces the award of restricted
share units ("RSUs") under the Company's amended and restated
restricted share unit plan approved by shareholders at the annual
general and special meeting of shareholders held on September 10, 2020.
On February 8, 2021, the board of
directors approved a grant of RSUs to one new and one existing
director, and a new officer of the Company, in accordance with the
terms of the respective agreements between the Company and each
individual, as set forth below.
Name
|
Title/Position
|
Number of
Shares
|
Vesting
Schedule
|
Juan Carlos
Echeverry
|
Director
|
425,532
|
RSUs will vest in
thirds on each of the first, second and third anniversaries of the
grant date
|
Deborah
Rosati
|
Director
|
212,766
|
RSUs will vest in
thirds on each of the first, second and third anniversaries of the
grant date
|
Joel
Friedman
|
CFO
|
250,000
|
125,000 RSUs will
vest as follows:
- 62,500 RSUs on the
grant date;
- 31,250 on May 26,
2021;
- 31,250 on November
26, 2021
The remaining 125,000
RSUs will vest as follows:
- 50% upon the
completion of a specified performance target
- 25% on each of the
first and second 6-month anniversaries thereafter
|
|
TOTAL
|
888,298
|
|
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North
America. Khiron is the leading medical cannabis provider in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Colombia, Peru and the UK, and is positioned to commence
sales of medical cannabis in Germany and Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and UK. The Company is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-grants-of-restricted-share-units-301225467.html
SOURCE Khiron Life Sciences Corp.